announced that its semaglutide product did not receive regulatory approval in Canada due to failure to meet required standards set by Canadian health authorities. This setback hinders the company's expansion plans in the Canadian pharmaceutical market for diabetes and obesity treatment. The rejection underscores the stringent regulatory environment for complex biologics like semaglutide. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.